Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol. 2018;31(2):214-234.

Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, et al. Publisher Correction: Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;563(7731):E24.

Goyal A, Street J, Alperstein SA, Siddiqui MT. HPV test result monitoring of different Bethesda categories in gynaecologic cytology: A valuable quality assurance measure. Diagn Cytopathol. 2018;46(11):914-918.

Greenblatt MB. Commentary. Clin Chem. 2018;64(4):642-643.

Russo V, Paciocco A, Affinito A, Roscigno G, Fiore D, Palma F, et al. Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. Mol Ther Nucleic Acids. 2018;13:334-346.

Hartono C, Chung M, Perlman AS, Chevalier JM, Serur D, Seshan SV, et al. Bortezomib for Reduction of Proteinuria in IgA Nephropathy. Kidney Int Rep. 2018;3(4):861-866.

Navrazhina K, Petukhova T, Wildman HF, Magro CM, Minkis K. Endocrine mucin-producing sweat gland carcinoma of the scalp treated with Mohs micrographic surgery. JAAD Case Rep. 2018;4(9):887-889.

Reina-Campos M, Shelton PM, Diaz-Meco MT, Moscat J. Metabolic reprogramming of the tumor microenvironment by p62 and its partners. Biochim Biophys Acta Rev Cancer. 2018;1870(1):88-95.

Reid EG, Looney D, Maldarelli F, Noy A, Henry D, Aboulafia D, et al. Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. Blood Adv. 2018;2(24):3618-3626.

Pal S, Postnikoff SD, Chavez M, Tyler JK. Impaired cohesion and homologous recombination during replicative aging in budding yeast. Sci Adv. 2018;4(2):eaaq0236.